Karen E. Knudsen, PhD, discusses the greater significance of the INTerpath-001 results of intismeran autogene in resectable melanoma.
Karen E. Knudsen, MBA, PHD
Advertisement
Articles by Karen E. Knudsen, MBA, PHD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
How Patient Factors Steer Treatment Selection in Metastatic Melanoma
5